7 research outputs found
Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment
Activin-A is expressed in bone and seems to regulate osteoclastogenesis.
In this study, serum activin-A was increased in postmenopausal women
with low bone mass and was positively correlated to age and negatively
to lumbar spinal bone mineral density (BMD). Serum activin-A levels did
not change 3 months after zoledronic acid infusion.
The aims of the study were to evaluate prospectively the circulating
activin-A levels in postmenopausal women with low bone mass and explore
possible correlations with clinical and laboratory data, as well as the
3-month effect of zoledronic acid infusion.
Postmenopausal women with low bone mass assigned to receive zoledronic
acid infusion (Patients, n = 47) and age-matched, postmenopausal women
with normal bone mass (Controls, n = 27) were recruited on an outpatient
basis. Main outcome measurement was serum activin-A levels.
Serum activin-A was higher in patients at baseline compared to controls
(p < 0.001) and activin-A in the serum of patients and controls was
positively correlated with age (Spearman’s coefficient of correlation
[rs] = 0.325; p = 0.005) and negatively with lumbar spinal (LS) BMD
(rs = -0.425; p < 0.001). In multiple linear regression analysis, only
age (B = 8.93; 95 % CI = 4.39-13.46; p < 0.001) was associated with
serum activin-A levels at baseline, independent from group (patients or
controls), previous anti-osteoporotic treatment, LS BMD and
follicle-stimulating hormone. Circulating activin-A levels were not
affected 3 months after zoledronic acid infusion.
Serum activin-A is increased in postmenopausal women with low bone mass
compared with postmenopausal women with normal bone mass and is
positively correlated to age and negatively to LS BMD
Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: The 3-month effect of zoledronic acid, denosumab or teriparatide treatment
Objective: The evaluation of circulating semaphorin-4D (sema4D) and plexin-B1 in postmenopausal women with low bone mass and the effect of antiresorptive or osteoanabolic treatment.Methods: Serum samples were obtained from postmenopausal women with low bone mass at baseline and 3 months after zoledronic acid infusion (n = 30), denosumab injection (n = 30) or teriparatide initiation (n = 28) and from controls matched for age, age at menopause and body mass index (n = 30) at the same time points.Main outcome measures: Circulating sema4D and plexin-B1.Results: Circulating sema4D increased following denosumab (p = 0.026), whereas decreased following teriparatide (p = 0.013). Sema4D/plexin-B1 ratio increased following denosumab (p = 0.004). At baseline, sema4D and plexin-B1 levels were higher in patients pre-treated with bisphosphonates compared to naïve ones (p < 0.001 and p = 0.001, respectively). In bivariate correlations sema4D was inversely correlated with serum carboxyterminal telopeptide of type 1 collagen (rs-0.282, p = 0.002), intact parathyroid hormone (rs-0.388, p < 0.001) and 25(OH)D (rs-0.316, p < 0.001), whereas there was a trend towards correlation with lumbar spine bone mineral density (rs-0.191, p = 0.053).Conclusions: Sema4D levels are independently associated with previous bisphosphonate treatment, intact parathyroid hormone and 25(OH)D levels. Denosumab and teriparatide seem to exert an opposite effect on circulating sema4D levels. Further studies are needed to evaluate whether sema4D mediates the coupling effect that occurs following both antiresorptive and osteoanabolic treatment. © 2014 Informa UK, Ltd
Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass
Bone and mineral researc
The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis
Introduction: GnRH-analogs induce bone loss. We aimed to investigate the effects of goserelin-induced menstrual cessation (MC) and subsequent menstrual restoration (MR) on bone metabolism (BM). Methods: In this prospective cohort study, premenopausal women (PMW) with histologically verified endometriosis (n = 21) received goserelin monthly for 6 months (6 m) resulting in MC and were followed up for another 6 m after MR (12 m). Age- and BMI-matched healthy PMW (n = 20) served as controls for bone mineral density (BMD) measurements. The primary endpoint was changes in lumbar spine (LS)-BMD at 6 m and 12 m; Secondary endpoints were changes in femoral neck (FN)-BMD, bone turnover markers (P1NP and CΤx), sclerostin, and expression of bone-related circulating microRNAs (miRNAs) at 6 m and 12 m. Results: Goserelin-induced MC reduced LS- and FN-BMD at 6 m (both p < 0.001). From 6 m to 12 m, LS-BMD increased (p < 0.001) but remained below baseline values (p = 0.012), whereas FN-BMD remained stable (p = 1.000). CTx and P1NP levels increased at 6 m (both p < 0.001) and decreased at 12 m (p < 0.001 and p = 0.013, respectively), while CTx (p = 1.000) alone and not P1NP (p = 0.020) returned to baseline. Sclerostin levels did not change. Relative expression of miRNAs targeting RUNX 2 and beta-catenin was significantly downregulated at 6 m compared to baseline (p < 0.001), while the expression of miRNAs targeting osteoblast and osteoclast function at both directions demonstrated a robust increase (up to 400fold) at 12 m (p < 0.001). Conclusions: Six months of goserelin-induced MC lead to significant bone loss associated with increased bone turnover and changes in the expression of bone-related miRNAs, changes that are only partially reversed at 6 m after MR. © 2022 Elsevier Inc